What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Is NHS ready to use real-world data to find new therapies and ways to bring drugs to patients?
Medtech companies can provide the tools to empower patients and HCPs.
Pharma must prepare its case meticulously to support its new drug applications.
Putting the who, where and why of real-world studies into context.
Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
RWE must become a fundamental accompaniment to traditional RCT data.
Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
